() () share price rose by 14% from 10.5 cents to 12.5 cents over the course of November and the stock is up a further 36% to date in December, last closing at 17 cents.
As cannabis becomes more mainstream, consumer market data that is emerging from several US states appears to show an increasing demand for higher-priced products which indicates increasing brand loyalty and consumers becoming more discriminating in terms of quality.
This is a trend seen in the alcohol and beverage sector in the past as consumer palates become more sophisticated.
MMJ is witnessing similar trends within the Canadian space as well which bodes well for its investment strategy of focusing on companies producing higher quality/higher margin flower and extracts combined with strong branding strategies.
Updates from MMJ’s investment portfolio:
Embark Health Inc. announced that it has been granted an amendment to its Health Canada licence for the sale of cannabis extracts, cannabis topicals and edible cannabis products from their facility in Delta, British Columbia.
The amendment to the Health Canada licence permits sales of Cannabis 2.0 products directly to Canadian Provinces & Territories and allows the company to…